Treatment-Induced Changes in Circulating Lymphocyte Populations Associate With Survival of Patients With Hepatocellular Carcinoma (HCC) and Intrahepatic Cholangiocarcinoma (ICC) Treated With Hypofractionated Proton Therapy (HPT)